Sarepta Therapeutics (NASDAQ:SRPT) Given New $25.00 Price Target at Deutsche Bank Aktiengesellschaft
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lowered by Deutsche Bank Aktiengesellschaft from $50.00 to $25.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a hold rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. Oppenheimer reduced their price target on shares […]
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lowered by Deutsche Bank Aktiengesellschaft from $50.00 to $25.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a hold rating on the biotechnology company’s stock. SRPT has been the topic of several other research reports. Oppenheimer reduced their price target on shares […]
